Renin inhibition: The holy grail of renin-angiotensin system blockade?

Journal of Human Hypertension

Volumn 21, Issue 10, 2007, Pages 766-769

  McInnes, G T ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALISKIREN; ANGIOTENSIN I; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; INSULIN; IRBESARTAN; LISINOPRIL; LOSARTAN; PLACEBO; RENIN; RENIN INHIBITOR; THIAZIDE DIURETIC AGENT; VALSARTAN;

ANGIONEUROTIC EDEMA; ANTIHYPERTENSIVE ACTIVITY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COUGHING; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HEART PROTECTION; HUMAN; HYPERKALEMIA; HYPERTENSION; INSULIN SENSITIVITY; MONOTHERAPY; NONHUMAN; NOTE; PLASMA RENIN ACTIVITY; RECEPTOR BLOCKING; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SIDE EFFECT;

AMIDES; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; FUMARATES; HUMANS; HYPERTENSION; LISINOPRIL; RENIN; RENIN-ANGIOTENSIN SYSTEM; TREATMENT OUTCOME;

EID: 34648831723     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/sj.jhh.1002221     Document Type: Note

References (28)

1. Strasser RH, Puig JG, Farsang C, Croket M, Li J, Van Ingen H. A comparison of the tolerability of the direct renin inhibitor aliskiren and lisinopril in patients with severe hypertension. J Hum Hypertens 2007; 21: 780-787 (this issue).
2. Ibrahim MM. Renin angiotensin system inhibition in hypertension. J Hum Hypertens 2006; 20: 101-108.
3. Bühler FR, Laragh JH, Baer J, Vaughan Jr ED, Brunner HR. Propranolol inhibition of renin secretion: A specific approach to diagnosis and treatment of renin-dependent hypertensive diseases. N Engl J Med 1972; 287: 1209-1214.
4. Tenenbaum A, Grossman E, Shemesh J, Fisman EZ, Nosrati I, Motro M. Intermediate but not low dose aspirin can suppress angiotensin-converting enzyme inhibitor-induced cough. Am J Hypertens 2000; 13: 776-782.
5. Nussberger J, Gugno M, Amstatz C, Cirardi M, Pellacani A, Agostoni A. Plasma bradykinin in angiooedema. Lancet 1998; 351: 1693-1697.
6. Brunner HR, Gavras H, Laragh JH, Keenan R. Hypertension in man. Exposure of the renin and sodium components using angiotensin II blockade. Circ Res 1974; 24(Suppl 1): 135-143.
7. Fisher NDL, Hollenberg NK. Renin inhibition: What are the therapeutic opportunities? J Am Soc Nephrol 2005; 16:292-299.
8. Wood J, Cumin F, Maibaum J. Pharmacology of renin inhibitors and their application to the treatment of hypertension. Pharmacol Ther 1994; 61: 325-344.
9. Skeggs Jr LT, Kahn JR, Lentz K, Shumway NP. The preparation, purification and amino acid sequence of a polypeptide renin substrate. J Exp Med 1957; 106: 439-453.
10. Hollenberg NK, Fisher ND, Price DA. Pathways for angiotensin II generation in intact human tissue: Evidence from comparative pharmacological interruption of the renin system. Hypertension 1998; 32: 387-392.
11. Laragh JH. The renin system and four lines of hypertension research: nephron heterogeneity, the calcium connection, and the prorenin vasodilator limb and plasma renin and heart attack. Hypertension 1992; 2: 267-279.
12. Alderman MH, Madhavan SH, Ooi WL, Cohen H, Sealey JE, Laragh JH. Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. N Engl J Med 1991; 324: 1098-1104.
13. Alderman MH, Ooi WL, Cohen H, Maldaven S, Sealey JE, Laragh JH. Plasma renin activity: A risk factor for myocardial infarction in hypertensive patients. Am J Hypertens 1997; 10: 1-8.
14. Luetscher JA, Kraemer FB, Wilson DM, Schwartz HC, Bryer-Ash M. Increased plasma renin activity in diabetes mellitus: A marker of microvascular complications. N Engl J Med 1985; 312: 1412-1417.
15. Lin C, Frishman WH. Renin inhibition: A novel therapy for cardiovascular disease. Am Heart J 1996; 131; 1024-1034.
16. Nguyen G, Delarue F, Burckle C, Bouzhir L, Giller T, Straer J-D. Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest 2002; 10: 1417-1427.
17. Wood JM, Stanton JL, Hofbauer KG. Inhibitors of renin as potential therapeutic agents. J Enzym Inhib 1987; 1: 169-185.
18. Karalliedde J, Viberti G. Evidence for renoprotection by blockade of the reiiin-angiotensin-aldosterone system in hypertension and diabetes. J Hum Hypertens. 2006; 20: 239-253.
19. Webb DJ, Manhem PJ, Ball SG, Inglis G, Leckie BJ, Lever AF et al. A study of the renin inhibitor H142 in man. J Hypertens 1985; 3 653-658.
20. Wood J, Maibaum J, Rahuel J, Grütter MG, Cohen N-C, Rasetti V et al. Structure-based design of aliskiren, a novel orally effective renin inhibitor. Biochem Biophys Res Commun 2003; 308: 698-705.
21. Nussberger J, Wuerzner G, Jensen C, Brunner HR. Angiotensin II suppression in humans by the orally active renin inhibitor aliskiren (SPP 100). Comparison with enalapril. Hypertension 2002; 39: e1-e8.
22. Oh B-H, Mitchell J, Herron JR, Chung J, Khan M, Keefe DL. Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-h blood pressure control in patients with hypertension. J Am Coll Cardiol 2007; 49: 1157-1163.
23. Stanton A, Jensen C, Nussberger J, O'Brien E. Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren. Hypertension 2003; 42: 1137-1143.
24. Gradman AH, Schmieder RE, Lins RL, Nussberger J, Chiang Y, Bedigian W. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation 2005; 111: 1012-1018.
25. O'Brien E, Barton J, Nussberger J, Mulcahy D, Jensen C, Dicker P et al. Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker. Hypertension 2007; 49: 276-284.
26. Villamil A, Chrysant SG, Camoun D, Schober B, Hsu H, Matrisciano-Dimichino L et al. Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. J Hypertens 2007; 25: 217-226.
27. Kim S, Iwao H. Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal disease. Pharmacol Rev 2000; 52: 11-34.
28. Julius S, Nesbitt SD, Egan BM, Weber MA, Michelson EL, Kaciroti N et al. Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med 2006; 354: 1-13.